Could skipping pills save money without hurting treatment?
NCT ID NCT07077161
First seen Dec 16, 2025 · Last updated May 12, 2026 · Updated 16 times
Summary
This study looks at whether taking cabozantinib less often (skipping doses) works just as well as the usual way of lowering the dose for people with advanced kidney cancer. About 34 adults who are already on a stable dose will try both methods for 4 weeks each. Researchers will check drug levels in the blood and ask about side effects and quality of life to see if skipping doses is a safe and cost-saving option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LUMC
RECRUITINGLeiden, South Holland, 2333ZA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.